Abstract 13P
Background
Breast conserving surgery and post mastectomy breast irradiation has been established as a standard care for early breast cancer. RT dose of 45-50 Gy in 1.8-2 Gy per fraction & 42.5 Gy at 2.66 Gy per fraction. Tumor bed boost is recommended in patients at higher risk for local failure, age < 50 years, positive axillary nodes, LVSI, or close margins. Typical doses are 10-16 Gy at 2 Gy per fraction. All dose schedules are given 5 days per week. Post mastectomy regional radiotherapy (PMRT) is effective at preventing locoregional failure (LRF).
Methods
All patients were staged accordingly. Data collection would be in tabulated sheet. This retrospective chort study conducted in cancer center, CMH, Dhaka, Bangladesh, including patients with carcinoma of breast treated with hypofractionated radiotherapy during last 03 year. The patient treated with 3DCRT, IMRT by LINAC, 6 MV photon and appropriate electron energy.
Results
Out of 82 patients,12 had undergone BCS and 70 mastectomy. Mean age of population was 52 years. 80% were T1&T2 in BCS group whereas most patients in mastectomy group had T3&T4 (60%). 45% were node negative in BCS group. TNBC accounted for 13% and their mean age was 43 yrs. Acute skin toxicity at the end of treatment was Grade 1 in 94% of mastectomy group and 71% in BCS group. Grade 2 toxicity was 6% in mastectomy group and 23% in BCS group. Grade 3 was 6% in BCS group. No grade 3 toxicity in mastectomy patients and grade 4 skin toxicity in any case. Post RT at 1 month; 39% of BCS patients had Grade I skin reaction which was only 7% in mastectomy patients. At 3 months post RT, 18% patients had persisting hyperpigmentation. At 6 months 8% patients had persisting erythema in the BCS group only. 3% of BCS and 8% of mastectomy patients had lymph edema till the date of evaluation. Cosmetic outcome in BCS patients remained good to excellent 6 months post surgery and radiotherapy. 1 patient of BCS and 3 patients of mastectomy had developed metastatic disease at the time of evaluation.
Conclusions
Hypofractionated RT is well tolerated with less acute skin toxicity and good cosmetic outcome. Regimens such as these should be encouraged in other centre to increase machine output time. The study is on-going to assess long term results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
19P - Cardiac and lung sparing radiotherapy in breast and chest wall irradiation with surface guided radiotherapy using deep inspiratory breath hold technique
Presenter: Ravi Shankar Bellala
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01